Table 2.
Association of miR-21, CEA, and CA125 expression with the clinical stage.
| Clinical stage | N | Serum miR-21 | miR-21 in PMBCs | CA199 | CEA | ||||
|---|---|---|---|---|---|---|---|---|---|
| Expression | Positive rate (%) | Expression | Positive rate (%) | Expression (U/mL) | Positive rate (%) | Expression (U/mL) | Positive rate (%) | ||
| I | 9 | 32.41 (22.53–52.13) | 88.88∗# (8/9) | 33.12 (23.55–52.32) | 88.88∗# (7/9) | 22.66 (8.23–55.12) | 44.44 (4/9) | 16.3 (8.75–54.43) | 33.33 (3/9) |
| II | 11 | 32.33 (21.65–52.77) | 90.90∗# (10/11) | 31.22 (22.55–50.11) | 81.81∗# (9/11) | 30.85 (22.89–89.43) | 54.54 (6/11) | 48.91 (19.75–78.93) | 45.45 (5/11) |
| III | 10 | 33.08 (23.01–53.68) | 90.00∗# (9/10) | 31.83 (22.79–49.94) | 90.00∗# (9/10) | 48.44 (33.77–88.88) | 40.00 (4/10) | 57.99 (21.33–88.12) | 50.00 (5/10) |
| IV | 18 | 31.11 (19.65–49.44) | 94.44∗# (17/18) | 30.88 (23.01–50.65) | 94.44∗# (17/18) | 67.82 (45.75–120.93) | 61.11 (11/18) | 66.8 (26.57–138.64) | 55.55 (10/18) |
| Total | 50 | 32.56 (22.24–54.17) | 88.00∗# (44/50) | 31.75 (22.62–48.98) | 84.00∗# (81/90) | 46.99 (29.53–100.11) | 50.00 (25/50) | 36.77 (22.11–88.65) | 46.00 (23/50) |
∗ p < 0.05 (versus CEA).
# p < 0.05 (versus CA125).